Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016

  • Email
  • Help

News

16/12/2016

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016

Seven medicines recommended for authorisation, 81 overall in 2016

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines for marketing authorisation at its December 2016 meeting. This brings the total number of medicines recommended for approval by the CHMP in 2016 to 811.

The CHMP recommended granting a marketing authorisation to Olumiant (baricitinib) for the treatment of moderate to severe active rheumatoid arthritis. For more information, please see the press release in the grid below.

The CHMP recommended granting a conditional marketing authorisation for Alecensa (alectinib) for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

Lifmior (etanercept) received a positive recommendation from the Committee for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis.

A biosimilar medicine, Truxima (rituximab), received a positive opinion from the CHMP for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

One hybrid medicine, Ledaga (chormethine), received a positive opinion for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma. Hybrid applications rely in part on the results of pre-clinical tests and clinical trials for a reference product and in part on new data. Ledaga has an orphan designation.

A generic medicine, Pregabalin Zentiva k.s (pregabalin), received a positive opinion from the Committee for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder.

The CHMP also granted a positive opinion for the informed consent application for Vihuma (simoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A (congenital factor VIII deficiency). In an informed consent application, reference is made to an authorised medicine and the marketing authorisation holder of the reference medicine has given consent to the use of their dossier in the application procedure.

Positive opinion on Zinplava adopted by written procedure

In addition to the positive opinions for the seven new medicines adopted at the December 2016 meeting, the CHMP recommended granting a marketing authorisation for Zinplava (bezlotoxumab) to prevent the recurrence of Clostridium difficile infection via written procedure on 22 November 2016.

Nine recommendations on extensions of therapeutic indications

The Committee recommended extensions of indications for Ameluz, Cinryze,Ilaris, Jardiance, Jentadueto, Keytruda, Tivicay, Trajenta and Votubia.

Start of referral: Micro Therapeutics Research Labs, India

The CHMP started a review of medicinesfor which studies have been conducted by Micro Therapeutic Research Labs at two sites in India. This follows a good clinical practice inspection which raised concerns about the study data used to support marketing authorisation applications of some medicines in the European Union. For more information, please see the start of referral document in the grid below.

Outcome of review of direct-acting antivirals

The CHMP confirmed the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) to screen all patients for hepatitis B before starting treatment with direct-acting antivirals for hepatitis C; patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines. These measures aim to minimise the risk of hepatitis B re-activation with direct-acting antivirals. For more information, please see the public health communication in the grid below.

Withdrawals of applications

Applications for marketing authorisations for Cavoley (pegfilgrastim), Efgratin (pegfilgrastim), Graspa (eryaspase) and Kepnetic (aceneuramic acid) have been withdrawn. Questions-and-answers documents on these withdrawals are available in the grid below.

A request to extend the indication of Arzerra (ofatumumab) to be used in a new combination with bendamustine for the treatment of relapsed chronic lymphocytic leukaemia has been withdrawn. A questions-and-answers document on this withdrawal is available below.

Agenda and minutes

The agenda of the December 2016 CHMP meeting is published on EMA’s website. Minutes of the November 2016 CHMP meeting will be published next week.

CHMP statistics

Key figures from the December 2016 CHMP meeting are represented in the graphic below.

More information on this, and all other outcomes of the CHMP’s December 2016 meeting, is available in the grid below.


1EMA will publish its human medicines highlights for 2016 in early 2017.

 

Download image in PDF format

Positive recommendations on new medicines

Name of medicineAlecensa
International non-proprietary name (INN)alectinib
Marketing-authorisation applicantRoche Registration Limited
Therapeutic indicationTreatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
More informationSummary of opinion for Alecensa

 

Name of medicineLifmior
INNetanercept
Marketing-authorisation applicantPfizer Limited
Therapeutic indicationTreatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis
More informationSummary of opinion for Lifmior

 

Name of medicineOlumiant
INNbaricitinib
Marketing-authorisation applicantEli Lilly Nederland B.V.
Therapeutic indicationTreatment of rheumatoid arthritis
 

Summary of opinion for Olumiant

 

Press release: New oral treatment for rheumatoid arthritis

 

Positive recommendation on new informed-consent application

Name of medicineVihuma
INNsimoctocog alfa
Marketing-authorisation applicantOctapharma AB
Therapeutic indicationTreatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)
More informationSummary of opinion for Vihuma

 

Positive recommendation on new generic medicine

Name of medicinePregabalin Zentiva k.s.
INNpregabalin
Marketing-authorisation applicantZentiva k.s.
Therapeutic indicationTreatment of neuropathic pain, epilepsy and generalised anxiety disorder
More informationSummary of opinion for Pregabalin Zentiva k.s.

  

Positive recommendation on new hybrid medicine

Name of medicineLedaga
INNchlormethine
Marketing-authorisation applicantActelion Registration Ltd
Therapeutic indicationTreatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL)
More informationSummary of opinion for Ledaga

 

Positive recommendation on new biosimilar medicine

Name of medicineTruxima
INNrituximab
Marketing-authorisation applicantCelltrion Healthcare Hungary Kft.
Therapeutic indicationTreatment of Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis and granulomatosis with polyangiitis and microscopic polyangiitis
More informationSummary of opinion for Truxima

  

Positive recommendations on extensions of therapeutic indications

Name of medicineAmeluz
INN5-aminolevulinic acid
Marketing-authorisation holderBiofrontera Bioscience GmbH
More informationSummary of opinion for Ameluz

   

Name of medicineCinryze
INNc1-esterase inhibitor, human
Marketing-authorisation holderShire Services BVBA
More informationSummary of opinion for Cinryze

  

Name of medicineIlaris
INNcanakinumab
Marketing-authorisation holderNovartis Europharm Ltd
More informationSummary of opinion for Ilaris

  

Name of medicineJardiance
INNempagliflozin
Marketing-authorisation holderBoehringer Ingelheim International GmbH
More informationSummary of opinion for Jardiance

 

Name of medicineJentadueto
INNlinagliptin / metformin
Marketing-authorisation holderBoehringer Ingelheim International GmbH
More informationSummary of opinion for Jentadueto

 

Name of medicineKeytruda
INNpembrolizumab
Marketing-authorisation holderMerck Sharp & Dohme Limited
More informationSummary of opinion for Keytruda

   

Name of medicineTivicay
INNdolutegravir
Marketing-authorisation holderViiV Healthcare UK Limited
More informationSummary of opinion for Tivicay

 

Name of medicineTrajenta
INNlinagliptin
Marketing-authorisation holderBoehringer Ingelheim International GmbH
More informationSummary of opinion for Trajenta

 

Name of medicineVotubia
INNeverolimus
Marketing-authorisation holderNovartis Europharm Ltd
More informationSummary of opinion for Votubia

  

Start of referral

Name of medicineMicro Therapeutics Research Labs, India
More informationStart of a review concerning the conduct of studies at Micro Therapeutic Research Labs, India

 

Public health recommendation

Name of medicineDirect-acting antivirals indicated for the treatment of hepatitis C (interferon free)
More informationDirect-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B

 

Outcome of harmonisation procedure

Name of medicineLovenox and associated names
INNenoxaparin
More informationQuestions and answers on Lovenox and associated names (enoxaparin, solution for injection)

  

Withdrawals of applications

Name of medicineArzerra
INNofatumumab
More informationQuestions and answers on Arzerra

 

Name of medicineCavoley
INNpegfilgrastim
More informationQuestions and answers on Cavoley

 

Name of medicineEfgratin
INNpegfilgrastim
More informationQuestions and answers on Efgratin

 

Name of medicineGraspa
INNeryaspase
More informationQuestions and answers on Graspa

 

Name of medicineKepnetic
INNaceneuramic acid
More informationQuestions and answers on Kepnetic

 

Other outcomes

Name of medicineInovelon
INNrufinamide
Marketing-authorisation holderEisai Ltd
More informationQuestions and answers on Inovelon

 

Name of medicineRepatha
INNevolocumab
Marketing-authorisation holderAmgen Europe B.V.
More informationSummary of opinion for Repatha

 

Other updates

Recommendations on eligibility to PRIME scheme
Scientific advice and protocol assistance
Start of community reviews
Overview of (invented) names reviewed in November 2016 by the Name Review Group (NRG)

How useful is this page?

Average rating:

 Based on 11 ratings

Add your rating:

See all ratings
1 ratings
2 ratings
0 ratings
4 ratings
4 ratings

Related information

Related content

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly.

Contact point:

Tel. +44 (0)20 3660 8427
E-mail: press@ema.europa.eu
Follow us on Twitter @EMA_News